Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1945-1953

  Wallace Jr , Richard J ^a,b   Dukart, Gary ^c   Brown Elliott, Barbara A ^a   Griffith, David E ^b   Scerpella, Ernesto G ^c   Marshall, Bonnie ^c  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Baylor UT Houston Center for AIDS Research   (United States)

^c PFIZER INC   (United States)

Author keywords

Atypical mycobacterial infections; Cystic fibrosis; Non tuberculous mycobacteria; Pulmonary

Indexed keywords

AMIKACIN; AZITHROMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ETHAMBUTOL; IMIPENEM; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; MINOCYCLINE; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BODY WEIGHT DISORDER; BONE INFECTION; CHILD; CYSTIC FIBROSIS; DEATH; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; EXTRAPULMONARY INFECTION; FACE EDEMA; FEMALE; FEVER; HUMAN; HYPOGLYCEMIA; ILEUS; INSOMNIA; LIVER DYSFUNCTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS INFECTION; MYCOBACTERIUM CHELONAE INFECTION; NAUSEA; OPEN STUDY; PAIN; PERIPHERAL EDEMA; PNEUMONIA; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SALVAGE THERAPY; SCHOOL CHILD; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; THORAX PAIN; TINNITUS; TUBERCULOSIS; VEIN THROMBOSIS; VERY ELDERLY; VOMITING; WEIGHT REDUCTION; YOUNG ADULT; ADOLESCENT; ANALOGS AND DERIVATIVES; ATYPICAL MYCOBACTERIUM; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NAUSEA; NONTUBERCULOUS MYCOBACTERIA; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902506627     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku062     Document Type: Article

References (39)

1. Bodle EE, Cunningham JA, Della-Latta P et al. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008; 14: 390-6.
2. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
3. Aksamit TR. Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002; 23: 643-53.
4. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
5. Koh WJ, Kwon OJ, Kim EJ et al. NRAMP1 gene polymorphism and susceptibility to nontuberculous mycobacterial lung diseases. Chest 2005; 128: 94-101.
6. Olivier KN, NTM in CF Study Group. The natural history of nontuberculous mycobacteria in patients with cystic fibrosis. Paediatr Respir Rev 2004; 5 Suppl A: S213-6.
7. Phillips MS, von Reyn CF. Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis 2001; 33: 1363-74.
8. Han D, Lee KS, Koh WJ et al. Radiographic and CT findings of nontuberculous mycobacterial pulmonary infection caused by Mycobacterium abscessus. AJR Am J Roentgenol 2003; 181: 513-7.
9. Wallace RJ Jr, Brown-Elliott BA, Crist CJ et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-7.
10. Brown BA, Wallace RJ Jr, Onyi GO et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36: 180-4.
11. Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35: 773-5.
12. Woods GL, Bergmann JS, Witebsky FG et al. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 2000; 38: 656-61.
13. Swenson JM, Wallace RJ Jr, Silcox VA et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28: 807-11.
14. Nash KA, Brown-Elliott BA,Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
15. Leao SC, Tortoli E, Euzeby JP et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-3.
16. Koh WJ, Jeon K, Lee NY et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405-10.
17. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006; 26: 1099-110.
18. European Medicines Agency. Tygacil 50 mg Powder for Solution for Infusion (Updated 2/20/2013). http://www.medicines.org.uk/emc/ medicine/17779/SPC/Tygacil+50mg+powder+for+solution+for+infusion/ (10 December 2013, date last accessed).
19. Wyeth Pharmaceuticals Inc. TYGACILw (Tigecycline) Prescribing Information. http://labeling.pfizer.com/showlabeling.aspx?id=491 (10 December 2013, date last accessed).
20. McGovern PC, Wible M, El-Tahtawy A et al. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 2013; 41: 463-7.
21. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
22. Garcia-Agudo L, Garcia-Martos P, Jesus I et al. [Assessment of in vitro susceptibility to antimicrobials of rapidly growingmycobacteria by E-test]. Rev Med Chil 2009; 137: 912-7.
23. Babinchak T, Ellis-Grosse E, Dartois N et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-67.
24. Breedt J, Teras J, Gardovskis J et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-66.
25. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
26. Oliva ME, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
27. Sacchidanand S, Penn RL, Embil JM et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-61.
28. Fernández-Roblas R, Martín-de-Hijas NZ, Fernández-Martínez AI et al. In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 2008; 52: 4184-6.
29. Huang YC, Liu MF, Shen GH et al. Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 2010; 43: 401-6.
30. Gitti Z, Mantadakis E, Maraki S et al. Clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria from patients in Crete, Greece. Future Microbiol 2011; 6: 1099-109.
31. Zaidi S, Elidemir O, Heinle JS et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11: 243-8.
32. Al-Benwan K, Ahmad S, Mokaddas E et al. Diagnosis of endocarditis caused by Mycobacterium abscessus. Ann Saudi Med 2010; 30: 408-11.
33. Garrison AP, Morris MI, Doblecki Lewis S et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11: 541-8.
34. Regnier S, Cambau E, Meningaud JP et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis 2009; 49: 1358-64.
35. Schneider P, Monsel G, Veziris N et al. Successful treatment of nodular lymphangitis due to Mycobacterium chelonae in two immunosuppressed patients. Dermatol Online J 2011; 17: 8.
36. Huang CW, Chen JH, Hu STet al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013; 41: 218-23.
37. Lee CH, You HL, Wang JW et al. Prosthetic joint infection caused by Mycobacterium alvei in an elderly patient. J Clin Microbiol 2011; 49: 3096-8.
38. Prevotat A, Bonne S, Veziris N et al. [Mycobacterium abscessus pulmonary infection treated with tigecyclin-amikacin and cefoxitin in a diabetic patient]. Med Mal Infect 2011; 41: 446-8.
39. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.